clinical trial · NCT03985878
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
Duchenne Muscular DystrophyEteplirsen
brief summary
The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male participants with DMD who have successfully completed the 96-week eteplirsen Study 4658-102.
started
Jun 26, 2019
primary completion
Aug 31, 2022
completion
Aug 31, 2022
last updated
Aug 18, 2023
official title
An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients With Duchenne Muscular Dystrophy Who Have Completed Study 4658-102
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol